Many Accuray Incorporated(ARAY) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Accuray Incorporated was Downgraded by JP Morgan to Neutral on Dec 14, 2016.
Company has reported several Insider transactions to the SEC, on Nov 9, 2015, Joshua Levine (CEO) purchased 50,000 shares at 7.12 per share price.On Sep 1, 2015, Alaleh Nouri (SVP, General Counsel &) sold 957 shares at 6.80 per share price.
Accuray Incorporated Last issued its quarterly earnings results on Jan 31, 2017. The company reported $-0.11 EPS for the quarter, missing the analyst consensus estimate by $ -0.03. Analyst had a consensus of $-0.08. The company had revenue of $87.50 million for the quarter, compared to analysts expectations of $87.00 million. The companys revenue was down -19.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.08 EPS.
Accuray Incorporated (NASDAQ:ARAY) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.67 by 3 Brokerage Firm. 2 Wall Street Firms have rated the stock as a strong buys. 1 Brokerage Firms have advised hold.
Accuray Incorporated (NASDAQ:ARAY): 3 Brokerage firm Analysts have agreed with the mean estimate for the short term price target of $7.67 in Accuray Incorporated (NASDAQ:ARAY). However, the stock price could fluctuate by $ 1.53 from the estimate as it is suggested by the standard deviation reading. The higher estimate has been put at $9 price target with the lower price estimate is calculated at $6
Accuray Incorporated (NASDAQ:ARAY) rose 0.93% or 0.05 points on Tuesday and made its way into the gainers of the day. After trading began at $5.4 the stock was seen hitting $5.525 as a peak level and $5.35 as the lowest level. The stock ended up at $5.45. The daily volume was measured at 747,205 shares. The 52-week high of the share price is $6.39 and the 52-week low is $4.45. The company has a market cap of $452 million.
ACCURAY INCORPORATED based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 40,000 patients worldwide and currently more than 130 systems have been installed in leading hospitals in the Americas, Europe and Asia.